[1] |
MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu.
Correlation between 25(OH)D and metabolically related fatty liver in T2DM population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
|
[2] |
XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin.
Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
|
[3] |
XIAO Yue, LI Tangfei, XUE Qianfu.
Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
|
[4] |
HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu.
Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
|
[5] |
HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle.
Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
|
[6] |
ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen.
Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
|
[7] |
LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong.
Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
|
[8] |
LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei.
Research progress of virus-mediated gene therapy in type 2 diabetes mellitu
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
|
[9] |
DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian.
Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
|
[10] |
YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong.
Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
|
[11] |
BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong.
Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
|
[12] |
WU Yi, FANG Fang, CHEN Ying, Fan Junwei.
Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639.
|
[13] |
HUANG Yiting, SHEN Aizong.
Clinical research progress of afatinib therapy for lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
|
[14] |
LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun.
Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
|
[15] |
LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang.
Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
|